BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26134117)

  • 1. Clinical intervals and diagnostic characteristics in a cohort of prostate cancer patients in Spain: a multicentre observational study.
    Bonfill X; Martinez-Zapata MJ; Vernooij RW; Sánchez MJ; Suárez-Varela MM; de la Cruz J; Emparanza JI; Ferrer M; Pijoán JI; Ramos-Goñi JM; Palou J; Schmidt S; Abraira V; Zamora J;
    BMC Urol; 2015 Jul; 15():60. PubMed ID: 26134117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer incidence and newly diagnosed patient profile in Spain in 2010.
    Cózar JM; Miñana B; Gómez-Veiga F; Rodríguez-Antolín A; Villavicencio H; ; Cantalapiedra A; Pedrosa E
    BJU Int; 2012 Dec; 110(11 Pt B):E701-6. PubMed ID: 22989066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA; Chen MH; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing D'Amico risk groups in radical prostatectomy through the addition of magnetic resonance imaging data.
    Algarra R; Zudaire B; Tienza A; Velis JM; Rincón A; Pascual I; Zudaire J
    Actas Urol Esp; 2014 Nov; 38(9):594-9. PubMed ID: 24791621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer.
    Efstathiou JA; Chen MH; Renshaw AA; Loffredo MJ; D'Amico AV
    Cancer; 2007 Apr; 109(8):1493-8. PubMed ID: 17340594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
    Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
    Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bias due to missing SEER data in D'Amico risk stratification of prostate cancer.
    Elliott SP; Johnson DP; Jarosek SL; Konety BR; Adejoro OO; Virnig BA
    J Urol; 2012 Jun; 187(6):2026-31. PubMed ID: 22498210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical interval and diagnostic characteristics in a cohort of bladder cancer patients in Spain: a multicenter observational study.
    Bonfill X; Martinez-Zapata MJ; Vernooij RWM; Sánchez MJ; Suárez-Varela MM; De la Cruz J; Emparanza JI; Ferrer M; Pijoan JI; Palou J; Schmidt S; Madrid E; Abraira V; Zamora J;
    BMC Res Notes; 2017 Dec; 10(1):708. PubMed ID: 29212556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of increasing mortality with longer diagnostic intervals for five common cancers: a cohort study in primary care.
    Tørring ML; Frydenberg M; Hansen RP; Olesen F; Vedsted P
    Eur J Cancer; 2013 Jun; 49(9):2187-98. PubMed ID: 23453935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agent Orange exposure, Vietnam War veterans, and the risk of prostate cancer.
    Chamie K; DeVere White RW; Lee D; Ok JH; Ellison LM
    Cancer; 2008 Nov; 113(9):2464-70. PubMed ID: 18666213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinico-pathologic characterisation of metastatic prostate cancer in the Radiotherapy and Oncology Department, Ahmadu Bello University Teaching Hospital, Zaria-Nigeria: 2006-2009.
    Adewuyi SA; Mbibu NH; Samaila MO; Ketiku KK; Durosinmi-Etti FA
    Niger Postgrad Med J; 2013 Mar; 20(1):45-51. PubMed ID: 23661210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment trends for clinically localised prostate cancer. National population analysis: GESCAP group.
    Miñana B; Rodríguez-Antolín A; Gómez-Veiga F; Hernández C; Suárez JF; Fernández-Gómez JM; Unda M; Burgos J; Alcaraz A; Rodríguez P; Moreno C; Pedrosa E; Cózar JM;
    Actas Urol Esp; 2016 May; 40(4):209-16. PubMed ID: 26723895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
    Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
    Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active surveillance for the management of prostate cancer in a contemporary cohort.
    Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
    Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
    van den Bergh RC; Roemeling S; Roobol MJ; Aus G; Hugosson J; Rannikko AS; Tammela TL; Bangma CH; Schröder FH
    BJU Int; 2009 Jun; 103(11):1472-7. PubMed ID: 19154509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
    BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.